539018 POWER TWIN TWIN EA LUBE PRIMARY POWER Motorcycle Drivetrain & Transmission Gaskets & Seals


  1. Home
  2. 539018 POWER TWIN TWIN EA LUBE PRIMARY POWER
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
TWIN POWER 539018 TWIN POWER PRIMARY LUBE EA
Condition: New Brand:

TWIN POWER

Manufacturer: TWIN POWER Manufacturer Part Number:

539018

Unit of measure: EA Warranty: Yes
MPN:

539018

Country/Region of Manufacture: UNKNOWN
Disclaimer:: Images may contain part(s) that do not match the product for sale
published on tue nov 09 2021

539018 POWER TWIN TWIN EA LUBE PRIMARY POWER Motorcycle Drivetrain & Transmission Gaskets & Seals

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

539018 POWER TWIN TWIN EA LUBE PRIMARY POWER Motorcycle Drivetrain & Transmission Gaskets & Seals

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS